Audit 308984

Title: Basis of Presentation Accounting Policies: Expenditures reported on the Schedule are reported on the accrual basis of accounting. Such expenditures are recognized following the cost principles contained in the Uniform Guidance, wherein certain types of expenditures are not allowable or are limited as to reimbursement. De Minimis Rate Used: N Rate Explanation: Effective January 1, 2020, TB Alliance has been granted a provisional indirect cost rate for the existing U.S. Agency for International Development grant in the amount of 16.89%. In 2022, TB Alliance proposed a revised indirect cost rate in the amount of 15% and started to use this rate, which is pending approval. TB Alliance has elected not to use the 10% de minimis indirect cost rate allowed under Uniform Guidance. The accompanying schedule of expenditures of federal awards (the Schedule) includes the federal award activity of The Global Alliance for TB Drug Development, Inc. (TB Alliance) under programs of the federal government for the year ended December 31, 2023. The information in this Schedule is presented in accordance with the requirements of Title 2 U.S. Code of Federal Regulations Part 200, Uniform Administrative Requirements, Cost Principles, and Audit Requirements for Federal Awards (Uniform Guidance). Because the Schedule presents only a selected portion of the operations of TB Alliance, it is not intended to and does not present the financial position, changes in net assets, or cash flows of TB Alliance.